Search results for: Determining Value
Filter search results
Update: Value-Based Pricing in the UK
11 January 2011
Value-based pricing for new medicines, proposed as part of UK health care reform, would create a QALY-plus approach for drugs approved starting 1 January 2014. For new drugs, this would…
Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
1 February 2021
…adding a new medicine to a currently reimbursed medicine represents value for money to the health system. In markets that utilise cost-per-QALY approaches for assessing value, a clinically effective medicine…
From STEDI to STRIDES: Valuing broader health-system benefits of AMR diagnostics
21 July 2025
…value framework In our most recent report, we introduce seven value elements designed to highlight the broader value of AMR diagnostics in reducing AMR: Spectrum value: Enables use of narrow-spectrum…
Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
30 March 2023
…are met. HOW CAN VALUE BE REWARDED? The system should include a value-based top-up that incentivises the development of higher-value products. The broader value of the antibiotic should be evaluated…
OHE Seminar Launches ‘An EQ-5D-5L Value Set for England’
13 November 2014
…value set. For example, compared with the EQ-5D value set currently used in the UK, the EQ-5D-5L value set for England: contains a smaller proportion of states with negative values:…
Improving the Measurement of Valued Output in Primary Care in England
1 August 2022
…elements that confer value to the output. We chose the perspective of the healthcare decision maker in England, whose objective is to maximise health. Hence, valued output in this study…
An eye on sustainability at the Economist’s Future of Health Europe
30 October 2023
…examples. He also underlined the importance of thinking about a value-based healthcare approach when shaping the care pathway and reframing the common question of ‘can we afford to do this?’…
Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA
28 February 2019
…value at $46,000 per QALY. Yescarta, at $136,000 per QALY for non-Hodgkin lymphoma, was between “intermediate” and “low” value for money. Second, additional elements of value not usually included in…
The Value of Vaccines in Maintaining Health System Capacity in England
1 October 2021
…treat another. These opportunity costs demonstrate the need to consider health system capacity value, one of the so-called “broader value elements” that is often not fully captured in traditional value…